EP1669086A1 - Composition contenant du TGF-beta et des protéines pour traiter le psoriasis - Google Patents

Composition contenant du TGF-beta et des protéines pour traiter le psoriasis Download PDF

Info

Publication number
EP1669086A1
EP1669086A1 EP05002383A EP05002383A EP1669086A1 EP 1669086 A1 EP1669086 A1 EP 1669086A1 EP 05002383 A EP05002383 A EP 05002383A EP 05002383 A EP05002383 A EP 05002383A EP 1669086 A1 EP1669086 A1 EP 1669086A1
Authority
EP
European Patent Office
Prior art keywords
psoriasis
tgf
patient
composition
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP05002383A
Other languages
German (de)
English (en)
Inventor
Yves Pouliot
Sylvie Gauthier
Eric Lamiot
Najat Aattouri
Christina Juneau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advitech Solutions Inc
Original Assignee
Advitech Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/007,912 external-priority patent/US20060127493A1/en
Priority claimed from CA002489851A external-priority patent/CA2489851A1/fr
Application filed by Advitech Solutions Inc filed Critical Advitech Solutions Inc
Publication of EP1669086A1 publication Critical patent/EP1669086A1/fr
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Definitions

  • the present invention relates in general to the field of the treatment of psoriasis and related skin disorders, and more particularly to a non-toxic oral and topical formulation that includes a pharmaceutically effective amount of dairy proteins for the treatment of psoriasis and related immune system disorders.
  • T cell mediated immune responses appear to be responsible for the inflammation and hyperproliferation of keratinocytes.
  • Neutrophils are found in psoriatic lesions, associated with increased levels of plasminogen activator.
  • Psoriatic fibroblasts have increased levels of enzymes involved in collagen synthesis, secondary to expansion of the papillary dermis.
  • Psoriatic plaques comprise HLA-DR positive keratinocytes and Langerhans cells, and activated T cells expressing elevated levels of IL-2 receptors.
  • the typical lesion of psoriasis is a well-demarcated erythematous plaque, covered by thick, silvery scales. Psoriasis can become so extensive as to cause exfoliative erythroderma, in which the entire epidermal surface is in a state of hyperproliferation.
  • Gluttate psoriasis is a form of the disease following streptococcal pharyngitis, with widely distributed characteristic 1-3 cm lesions.
  • Pustular psoriasis is characterized by numerous sterile pustules of 2-5 mm in diameter, and may lead to an acute, explosive, life-threatening episode of fever, chills, leukocytosis, hypoalbuminemia, and hypocalcemia, demanding immediate, vigorous therapy.
  • Previously stable plaque-type psoriasis can be acutely exacerbated by viral infections, particularly HIV.
  • Psoriasis is also associated with five different forms of psoriatic arthritis, including distal interpharangeal involvement; an asymmetric, oligoarticular pattern; a symmetric polyarthritis; arthritis mutilans; and sacroiliitis and spondylitis.
  • the inflammation and hyperproliferation of psoriatic tissue is associated with a different histological and antigenic profile than normal skin.
  • a panel of anti-carbohydrate monoclonal antibodies as described in the art can be used to compare psoriatic tissue with the surrounding dermis.
  • the glycosylation pattern in psoriatic epithelium is changed in two ways: some carbohydrates are expressed at an earlier stage of cell maturation.
  • certain biosynthetic precursor antigens not expressed in normal skin were found in psoriatic skin.
  • Classical treatments of psoriasis include calcipotriene (a vitamin D 3 derivative), topical coal tar preparations, systemic antimitotic agents such as methotrexate, and retinoids, particularly etretinate.
  • Extensive psoriasis can be treated by photosensitization with oral 8-methoxypsoralen, followed by ultraviolet A. Corticosteroids are given for psoriatic arthritis and acute attacks of pustular psoriasis. More recently, cyclosporin A has been tested in clinical trials at doses of 3-7 mg/kg with promising results, but associated with the risk of renal toxicity.
  • 5,339,977 describes n-deacetyl-lysoganglioside derivatives for use as phospholipase A2 inhibitors for the treatment of proliferative and autoimmune diseases, including various forms of cancer, psoriasis, and rheumatoid arthritis.
  • IL-2 fusion toxin has been developed (Seragen, Inc.) that is designed to selectively destroy activated T cells in psoriatic plaques, leaving normal cells alone. The objective is to destroy activated T cells, and thereby clear the psoriasis.
  • a Phase II study has been performed in which test doses of 5, 10, and 15 ⁇ g/kg were administered per day. Comparable improvement was observed in patients with moderate to severe psoriasis. However, in order to obtain this response, the compound was administered three days per week for four weeks.
  • BCX-34 is a small molecule drug that inhibits purine nucleoside phosphorylase, a human enzyme believed to be involved in the proliferation of T cells.
  • An oral formulation is being tested in an ongoing Phase I/II trial. A topical formulation advanced to the Phase III stage for both lymphoma and psoriasis. The Phase III psoriasis study showed only a 14% greater improvement in mean lesion scores in the treated group compared to placebos, which for these studies was not statistically significant.
  • Another product available in the art consist in a chimeric human tumor necrosis factor ⁇ monoclonal antibody derived from mouse. It is made of the human constant and mouse variable regions of the IgG antibody. This agent is administered by intravenous infusion over at least 2 h and neutralizes soluble tumour necrosis factor ⁇ bound to cell membranes. Results of several case reports attest to the efficacy of this agent in treatment of psoriasis. Drawbacks of the drug include the need for slow intravenous infusion. A small but real proportion of patients have infusion reactions, including potentially serious reactions such as hypotension, rigors, and allergic reactions.
  • tumour necrosis factor ⁇ receptor fusion proteins consist of two extracellular ligand-binding domains of the human p75 tumour necrosis factor ⁇ receptor fused to the Fc portion of human IgGl. These fusion proteins are likely effective for psoriatic arthritis and seems to be safer than ciclosporin or methotrexate with no nephrotoxicity or hepatotoxicity.
  • Non-neutralising antibodies occur in less than 5% of patients.
  • Antinuclear antibodies and antibodies to double-stranded DNA have been reported, but full cases of systemic lupus erythematosus are rare.
  • Anticardiolipin antibodies also develop but have been attributed to minor concomitant infections. Because this agent is a tumour necrosis factor ⁇ inhibitor, concern has been raised about the potential for immunosuppression leading to infection.
  • Humanised anti-CD11 a monoclonal antibody was also developed for the treatment for moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis. It is normally administered as a subcutaneous (under the skin) injection, and is designed to inhibit the binding of immune system T-cells to other cell types and targets three key processes in the cascade of events that lead to autoimmune symptoms.
  • Another family of products is known in the art to prevent T cell activation by blocking the LFA-3/CD-2 pathway through binding to the CD2 receptor. It is an IV/IM administered product. Since this family of products may cause reduction in CD4+ and CD8+ T lymphocyte counts, it may not be appropriate for all individuals.
  • a fully human fusion protein consisting of a binding site of LFA-3 fused to the Fc portion of IgG1 CD45Ro+ memory T cells, which have a major role in development of psoriasis, maximally express CD2, a natural ligand of LFA-3 has been developed. By binding CD2, it prevents T-cell activation. Moreover, the Fc portion of the molecule engages Fc receptors on macrophages and NK cells, which results in apoptosis of the CD45RO+ T cells.
  • Another humanised monoclonal antibody to CD11A was developed, which is a component of LFA-1 on T cells and ICAM-1 on antigen-presenting cells is an important co-stimulatory signal resulting in T-cell activation.
  • ICAM-1 on endothelial cells also interacts with LFA-1 on circulating T cells, a necessary step for migration of T cells into inflamed skin. It can thus interfere with development of psoriasis by blocking T-cell migration into the skin and by preventing T-cell activation.
  • some patients developed flu-like symptoms including headache, chills, fever, nausea, vomiting, or myalgias. Symptoms arose on the day of injection or the following 2 days. These acute adverse events subsided by the third dose.
  • Systemic treatment has been used in patients with physically, socially, or economically disabling psoriasis that has not responded to topical treatment.
  • the choices to date have been phototherapy or systemic drug therapy.
  • systemic treatment has employed phototherapy with Ultraviolet B irradiation, photo chemotherapy which combines the photosensitizing drug methoxsalen with Ultraviolet A phototherapy (PUVA), methotrexate, etretinate, systemic corticosteroids, and cyclosporine.
  • PUVA Ultraviolet A phototherapy
  • methotrexate etretinate
  • systemic corticosteroids systemic corticosteroids
  • cyclosporine cyclosporine.
  • Each of these systemic treatments has variable efficacy and undesired side effects, and some of them are very toxic and present frequent relapses of the disease.
  • Keratinocyte function is regulated via intracellular signalling pathways triggered by growth factors and adhesion molecules.
  • the EGF family and the TGF- ⁇ family are thought to play central roles; they provide dual mode regulation of keratinocytes growth via the proliferation stimulating effect of EGF and the proliferation-inhibiting effect of TGF- ⁇ .
  • TGF- ⁇ s exert a wide range of biological effects on keratinocytes, such as growth inhibition, production of extracellular matrix, and synthesis of plasminogen activator and its inhibitor (PAI 1). Among them, growth inhibition is the most prominent.
  • TGF- ⁇ 1 and TGF- ⁇ 2 are synthesized and secreted in human keratinocytes. It seems that TGF- ⁇ 3 is not a major TGF- ⁇ in human keratinocytes growth. Vitamin D3 is a strong inhibitor keratinocyte growth. The involvement of TGF- ⁇ production induced by vitamine D3 increased the expression of TGF- ⁇ 2 mRNA 4 to 5 fold. In contrast, TGF- ⁇ 1 mRNA and TGF- ⁇ 3 mRNA were not increased.
  • TGF- ⁇ regulate autonomous growth of human keratinocytes
  • TGF- ⁇ antagonized the acanthotic and degenerative effect of TGF- ⁇ in involved psoriatic skin
  • TGF- ⁇ alone did not cause granular layers to appear in the involved psoriatic epidermis, indicating that TGF- ⁇ alone cannot normalize the psoriatic condition of the epidermis.
  • TGF- ⁇ is now recognized as a potent growth inhibitor for human keratinocytes.
  • TGF- ⁇ 2 which was found through the normal human epidermis, was decrease in the proriatic epidermis. Since TGF- ⁇ is a strong growth inhibitor for human keratinocytes this result indicates the possibility that the decrease of TGF- ⁇ 2 is involved in the pathogenesis of psoriasis. Therefore, the decrease in TGF- ⁇ 2 in psoriasis epidermis may induce the accelerated proliferation of keratinocytes and result in epidermal hyperplasia.
  • TGF- ⁇ is also a potent immunosuppressive agent.
  • TGF- ⁇ 2 may permit propagation of an immune/inflammatory reaction in the dermis and epidermis of involved psoriasis. It has been supposed that an immune-activation triggers the growth activation of epidermal keratinocytes in psoriasis.
  • EGF family growth factors TGF- ⁇ , amphiregulin and HB-EGF
  • KGF and IL-6 are well known as proliferation-stimulating growth factors.
  • TGF- ⁇ family growth factors are the major proliferation-inhibitory growth factors. The increase of TGF- ⁇ , amphiregulin and IL-6 was found in psoriasis. Autocrine- or cross-induction of EGF family growth factors may play an important role in epidermal hyperplasia.
  • IGFs insulin-like growth factors
  • IGF-I and IGF-II are ubiquitous peptides each with potent mitogenic effects on a broad range of cells. Molecules of the IGF type are also known as "progression factors” promoting "competent" cells through DNA synthesis.
  • the IGFs act through a common receptor known as the Type I or IGF-I receptor, which is tyrosine kinase linked. They are synthesized in mesenchymal tissues, including the dermis, and act on adjacent cells of mesodermal, endodermal or ectodermal origin. The regulation of their synthesis involves growth hormone (GH) in the liver, but is poorly defined in most tissues.
  • GH growth hormone
  • IGFBPs IGF binding proteins
  • Skin comprising epidermis and underlying dermis, has GH receptors on dermal fibroblasts. Fibroblasts synthesize IGF-I as well as IGFBPs-3, -4, -5 and -6, which may be involved in targeting IGF-I to adjacent cells as well as to the overlaying epidermis.
  • the major epidermal cell type, the keratinocyte does not synthesize IGF-I, but possesses IGF-I receptors and is responsive to IGF-I.
  • One aim of the present invention is to provide a composition and uses thereof for the prophylaxis or treatment of psoriasis or related disorders, said composition comprising between 0.1 to 5 ⁇ g of TGF- ⁇ 1 and between 5 to 50 ⁇ g of TGF- ⁇ 2 per gram of composition, and a total protein concentration completed to at least 15% (w/w), but preferably to at least 50% , and most preferably 80%, with dairy derived proteins.
  • TGF- ⁇ 1 and TGF- ⁇ 2 can also be dairy derived, and can be found at concentration between 0.2 to 1.2 ⁇ g/g and between 10 to 18 ⁇ g respectively per gram of composition.
  • composition may comprises additionally between about 0.1 to 15% of minerals as defined herein after.
  • At least 50% of the proteins are hydrosoluble.
  • 70%, and most preferably 80% of the proteins found in the composition are hydrosoluble.
  • the ratio of TGF- ⁇ 1+TGF- ⁇ 2/IGF-1 is preferably of between about 0.1 to 3.
  • types of psoriasis that can be prevented or treated with the method or composition of the present invention may include one of nail psoriasis, plaque psoriasis, guttate psoriasis, erythrodermic psoriasis, pustular psoriasis, hyperkeratosis, oncholysis, or psoriatic arthritis.
  • Another aim of the present invention is to provide a method for preventing or treating psoriasis or related disorders comprising administering to a patient between 0.1 to 5 ⁇ g of TGF- ⁇ 1 and between 5 to 50 ⁇ g of TGF- ⁇ 2 per gram of composition, and a total protein concentration completed to at least 80% (w/w) with dairy derived proteins.
  • one aspect of the present invention contemplates a method for ameliorating the effects of a proliferative and/or inflammatory skin disorder associated with psoriasis in a mammal, the method comprising treatment of the psoriasis and related diseases with an effective amount of a composition or chemical analogues thereof capable of having properties in preventing or treating psoriasis and related diseases.
  • psoriatic tissue refers to tissue affected by psoriasis and affected cells contained within the tissue, but not to cells that have migrated to the site such as leukocytes.
  • the psoriatic tissue is from a human.
  • an effective amount is intended to mean an amount sufficient to effect a beneficial or desired clinical result.
  • An effective amount can be administered in one or more doses.
  • an effective amount of growth factors and/or dairy derived proteins, or other composition is an amount that induces a treatment or prophylactic response against at least one psoriasis responsible factor.
  • polypeptide polypeptide
  • mammals include, but are not limited to, farm animals, sport animals, rodents, primates, and pets.
  • minerals as used herein is intended to mean salt constituents and minerals at concentrations normally found in dairy products. For example, there can be different concentration of calcium, phosphorus, magnesium, potassium, sodium, chloride, sulfur, and citric acid. This also means that trace elements known in the art as found in dairy products can be assimilated or inferred therein.
  • compositions and methods for treating psoriasis in an individual comprising administering a composition effective in stimulating a specific immunological response against a physiological imbalance aberrantly expressed in psoriatic tissue.
  • composition(s) comprise a cocktail of products that shares growth and regeneration characteristics of a growth factor that is aberrantly expressed in psoriatic tissue (such as human psoriatic tissue).
  • growth factors included in the composition of the present invention are not limited to transforming growth factors, such as TGF- ⁇ 1 and TGF- ⁇ 2, and at least 15% of dairy derived proteins.
  • the composition of the present invention will comprised of at least 40% or 50% of dairy derived proteins, and most preferably more than 80% of dairy derived proteins.
  • the proteins are hydrosoluble.
  • the proteins may be comprised, for example but not limited to, of at least 60% (w/w) of ⁇ -lactoglobulin, and/or between 0.1 to 30% (w/w) of lactoferrin.
  • Milk proteins are naturally presents as follows: grams/ litre % of total protein Total Protein 33 100 Total Caseins 26 79.5 alpha s1 10 30.6 alpha s2 2.6 8.0 beta 9.3 28.4 kappa 3.3 10.1 Total Whey Proteins 6.3 19.3 alpha lactalbumin 1.2 3.7 beta lactoglobulin 3.2 9.8 BSA 0.4 1.2 Immunoglobulins 0.7 2.1 Proteose peptone 0.8 2.4
  • whey proteins The proteins appearing in the supernatant of milk after precipitation at pH 4.6 are collectively called whey proteins. These globular proteins are more water soluble than caseins and are subject to heat denaturation. Native whey proteins have good gelling and whipping properties. Denaturation increases their water holding capacity.
  • the principle fractions are ⁇ -lactoglobulin, alpha-lactalbumin, bovine serum albumin (BSA), and immunoglobulins (Ig).
  • ⁇ -Lactoglobulins (MW - 18,000; 162 residues) This group, including eight genetic variants, comprises approximately half the total whey proteins. ⁇ -Lactoglobulin has two internal disulfide bonds and one free thiol group. The conformation includes considerable secondary structure and exists naturally as a noncovalent linked dimer. At the isoelectric point (pH 3.5 to 5.2), the dimers are further associated to octamers but at pH below 3.4, they are dissociated to monomers.
  • alpha-Lactalbumins (MW - 14,000; 123 residues) These proteins contain eight cysteine groups, all involved in internal disulfide bonds, and four tryptophan residues. alpha-Lactalbumin has a highly ordered secondary structure, and a compact, spherical tertiary structure. Thermal denaturation and pH ⁇ 4.0 results in the release of bound calcium.
  • Enzymes are a group of proteins that have the ability to catalyze chemical reactions and the speed of such reactions. The action of enzymes is very specific. Milk contains both endogenous and exogenous enzymes. Exogenous enzymes mainly consist of heat-stable enzymes produced by psychrotrophic bacteria: lipases, and proteinases. There are many endogenous enzymes that have been isolated from milk. The most significant group are the hydrolases: lipoprotein lipase; plasmin; and alkaline phosphatase.
  • Lipoprotein lipase A lipase enzyme splits fats into glycerol and free fatty acids. This enzyme is found mainly in the plasma in association with casein micelles. The milk fat is protected from its action by the fat globular matrix (FGM). If the FGM has been damaged, or if certain cofactors (blood serum lipoproteins) are present, the LPL is able to attack the lipoproteins of the FGM. Lipolysis may be caused in this way.
  • FGM fat globular matrix
  • Plasmin is a proteolytic enzyme; it splits proteins. Plasmin attacks both ⁇ -casein and alpha(s2)-casein. It is very heat stable and responsible for the development of bitterness in pasteurized milk and UHT processed milk. It may also play a role in the ripening and flavour development of certain cheeses, such as Swiss cheese.
  • Alkaline phosphatase Phosphatase enzymes are able to split specific phosporic acid esters into phosphoric acid and the related alcohols. Unlike most milk enzymes, it has a pH and temperature optima differing from physiological values; pH of 9.8. The enzyme is destroyed by minimum pasteurization temperatures, therefore, a phosphatase test can be done to ensure proper pasteurization.
  • the active compounds according to the invention are distinguished by strong antiinflammatory actions.
  • the active compounds are administered in order to decrease manifestations of the disease in frequency and strength.
  • Treatment in the manifest stage leads to its curtailment and to the alleviation of the symptoms.
  • the active compounds of the present composition can be used prophylactically and for the treatment of the disorders.
  • Plaque-type psoriasis is the most common form of the disease, occurring in more than 80% of cases.
  • Guttatte psoriasis occurs in about 10% of patients with psoriasis, and erythrodermic and pustular psoriasis each occur in fewer than 3% of patients.
  • Nail psoriasis is generally the first sign of disease in 4% of patients.
  • Between 5 to 10% of patients with psoriasis have psoriatic arthritis, a destructive and occasionally disabling joint disease. The course of psoriatic arthritis varies, with some having mild changes and others severe, rapid destruction of joints. Skin problems such as dryness or lesions are symptoms associated with psoriasis.
  • Erythrodermic psoriasis is characterized by generalized inflamed erythema and widespread scaling, affecting up to 100% of the body surface area. Patients lose many of the protective functions of the skin, including the skin's ability to protect against infection, control body temperature, and prevent loss of fluids and nutrients through the cutaneous surface.
  • Generalized pustules psoriasis is characterized by development of sterile pustules covering large portions of the trunk and extremities. In severe cases, pustules become confluent forming large areas of pus. In this case also, many of the skin's protective functions are lost, making patients susceptible to infection and loss of fluids and nutrients.
  • a further neurosensory phenomenon is to be regarded as itching in the case of atopic skin, and also itching in the case of psoriasis related disorders.
  • “Stinging” phenomena can be regarded as disorders to be treated cosmetically or orally, or in other cases by other ways of administration. Severe itching, however, in particular in the case of atopy, in particular neurodermatitis and severe itching of the skin occurring during psoriasis, can also be regarded as a relatively serious dermatological disorder.
  • the active compounds according to the invention can in particular also be used on skin superficially appearing to be healthy, e.g. in the case of psoriasis and atopy, i.e. also in addition to the diseased skin areas and, in particular, here too in the case of related psoriasis disorders.
  • the active compounds according to the invention can also be incorporated without problems into customary oral, pharmaceutical, dermatological, and cosmetic bases for preferred oral administrations and the corresponding pharmaceutical, in particular dermatological, and cosmetic topical preparations or compositions can thus be obtained.
  • concentration of compounds in the composition of the present invention are adjusted depending of the needs.
  • TGF- ⁇ 1 can be found at concentration of between 0.1 to 5 ⁇ g per gram of composition and TGF- ⁇ 2 can be found at concentration of between 5 to 50 ⁇ g per gram of composition.
  • TGF- ⁇ 1 is found at concentration of 0.2 to 1.2 ⁇ g/g
  • TGF- ⁇ 2 at between 10 to 18 ⁇ g/g of composition.
  • the preparations can be used daily in a customary manner.
  • the composition comprises at least 70% (w/w) of dairy derived proteins.
  • the total concentration of proteins in the composition would normally of at least 80%.
  • Dairy proteins or dairy products as used herein may include milk, colostrums, or whey proteins or derived products or fractions thereof.
  • the fat fraction of the composition can be generally found at concentration between about 0.5 to 10 % (w/w) in the composition.
  • the fat or compounds of this family of products can be derived from dairy products, or from any other source, such as for example, but not limited to, vegetable or animal sources, synthetic or natural sources, allowing the composition of the present invention to have its properties as defined herein.
  • the physical properties of milk fat can be summarized as follows: density at 20°C is 915 kg/m 3 ; refractive index (589 nm) is 1.462 which decreases with increasing temperature; solubility of water in fat is 0.14% (w/w) at 20°C and increases with increasing temperature; thermal conductivity is about 0.17 J/m/s/K at 20°C; specific heat at 40°C is about 2.1kJ/kg/K; electrical conductivity is ⁇ 10 -12 / ohm/cm; and dielectric constant is about 3.1.
  • the lipids are solid, therefore, are correctly referred to as "fat” as opposed to “oil” which is liquid at room temperature.
  • the melting points of individual triglycerides ranges from -75°C for tributyric glycerol to 72°C for tristearin.
  • the final melting point of milk fat is at 37°C because higher melting triglycerides dissolve in the liquid fat. This temperature is significant because 37°C is the body temperature of the cow and the milk would need to be liquid at this temperature.
  • the melting curves of milk fat are complicated by the diverse lipid composition: trans unsaturation increases melting points; and odd-numbered and branched chains decrease melting points.
  • the invention also relates to the use of the active compounds according to the invention for the production of pharmaceutical compositions, in particular oral, pharmaceutical and cosmetic compositions for the prophylaxis and treatment of psoriasis, allergies and auto-immune disorders and on dry skin and on sensitive skin.
  • compositions as oral, or topical preparations.
  • the present invention also addresses the underlying T-cell disorder that results in an inflammatory condition due to psoriasis.
  • the present inventors have recognized that most, if not all, of the current therapies for psoriasis or similar T-cell mediated inflammatory skin conditions are designed to eliminate T-cells and to thereby ameliorate inflammation. It is possible that a major problem with the current treatments is that the therapy itself is so toxic that it may promote recurrence during healing. The toxicity of current treatments unleashes some or all of the cytokines that are associated with the promulgation of these chronic and often rebounding skin diseases.
  • the active compounds according to the invention can be mixed with customary pharmaceutically tolerable diluents or vehicles and, if appropriate, with other auxiliaries and administered, for example, orally or parenterally. They can preferably be administered orally in the form of granules, capsules, pills, tablets, film-coated tablets, sugar-coated tablets, syrups, emulsions, suspensions, dispersions, aerosols and solutions and also liquids, or else also as suppositories, vaginal suppositories or parenterally, e.g. in the form of solutions, emulsions or suspensions. Preparations to be administered orally can contain one or more additives such as sweeteners, aromatizing agents, colorants and preservatives.
  • Tablets can contain the active compound mixed with customary pharmaceutically tolerable auxiliaries, for example inert diluents such as calcium carbonate, sodium carbonate, lactose and talc, granulating agents and agents which promote the disintegration of the tablets on oral administration, such as starch or alginic acid, binding agents such as starch or gelatin, lubricants such as magnesium stearate, stearic acid and talc.
  • auxiliaries for example inert diluents such as calcium carbonate, sodium carbonate, lactose and talc, granulating agents and agents which promote the disintegration of the tablets on oral administration, such as starch or alginic acid, binding agents such as starch or gelatin, lubricants such as magnesium stearate, stearic acid and talc.
  • Suitable excipients are, for example, lactose, gelatin, maize starch, stearic acid, ethanol, propylene glycol, ethers of tetrahydrofurfuryl alcohol and water.
  • the formulations are prepared, for example, by extending the active compounds with solvents and/or excipients, if appropriate using emulsifiers and/or dispersants, it being possible, for example, in the case of the use of water as a diluent optionally to use organic solvents as auxiliary solvents.
  • Administration is carried out in a customary manner, preferably orally or parenterally, in particular perlingually, sublingually, or intravenously.
  • tablets can also contain additives, such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives, such as starch, preferably potato starch, gelatin and the like.
  • lubricants such as magnesium stearate, sodium lauryl sulphate and talc can additionally be used for tableting.
  • the active compounds can be mixed, apart from with the above-mentioned auxiliaries, with various flavors enhancers or colorants.
  • solutions of the active compounds using suitable liquid excipients can be employed.
  • Capsules can contain the active compound as a single constituent or mixed with a solid diluent such as calcium carbonate, calcium phosphate or kaolin.
  • the injectable preparations are also formulated in a manner known per se .
  • Ointments and topical formulations are particularly of interest also when considering the use of the composition of the present invention for treating psoriasis.
  • compositions according to the invention can be formulated as liquid, pasty or solid preparations, for example as aqueous or alcoholic solutions, aqueous suspensions, emulsions, for example W/O or O/W emulsions, ointments, gels, lotions, creams, oils, powders or sticks.
  • the active compounds can be incorporated into pharmaceutical and cosmetic bases for topical application, which as further components contain, for example, oil components, fat and waxes, emulsifiers, anionic, cationic, ampholytic, zwitterionic and/or non-ionic surfactants, lower mono- and polyhydric alcohols, water, preservatives, buffer substances, thickeners, fragrances, colorants and opacifiers.
  • the emulsions e.g. W/O emulsions, or ointments are used.
  • antioxidants are added to the active compounds and to the pharmaceutical and topical preparations.
  • the use of natural or naturally identical compounds such as, for example, tocopherols is particularly preferred here.
  • the antioxidants mentioned are contained in the compositions according to the invention, for example, in amounts from 0.01-5% by weight, in particular from 0.5-2% by weight, based on the total composition.
  • Eligible patients were at least 18 years of age and diagnosed as having active plaque psoriasis with at least 2 % of total body surface area affected.
  • the score for the psoriasis area-and-severity index was the primary outcome measured by the physician.
  • the PASI combines assessments of psoriasis induced erythema, scaling and skin thickness, each weighted according to the size of the affected area.
  • the composite score ranges from 0 to 72.
  • PGA Physician's Global Assessment
  • Patient GA Patient's Global Assessment
  • Pruritus Assessment 4-point scale
  • BSA Body Surface Area
  • Safety measurements included the monitoring of adverse events throughout the study. In addition, vital signs (heart rate, blood pressure), eye examination, urinalysis, and blood chemistry (creatinine, albumin, total bilirubin, alanine transaminase ALT, aspartate transaminase AST) were assessed. Haematology analysis (complete blood count) was also performed. Safety measurements were performed at screening, at baseline and at days 28 and 56 of treatment.
  • a hydrating cream was provided to each participant for the duration of the trial.
  • the participant were allowed to use the cream whenever needed, except during the 24h-period before each visit.
  • XP-828L improved the score of psoriasis area-and severity index in 6 out of 11 subjects (55 %).
  • 7 of the 11 subjects had an improvement of their PASI score ranging from 9.5 to 81.3 %.
  • PASI 75 is the currently recognized benchmark of end points used in psoriasis clinical trials.
  • One patient experienced an increase in its PASI score of 13.6 %.
  • the PASI score remained unchanged. (Table 2). Table 1 Summary of the assessments at each patient's visit.
  • the PGA decreased for 2 patients (patient 4 and patient 9) after one month of treatment, and for 2 patients (patient 8 and patient 12) after 2 months of treatment by one point.
  • XP-828L was well tolerated. No clinically significant laboratory abnormalities or pattern of changes in vital signs were observed during the XP-828L treatment.
  • XP-828L may represent a safe way to treat psoriasis. Only one patient experienced fluctuations of his creatinine values but no fluctuation pattern was found and no other abnormalities were observed.
  • XP-828L showed to have the potential of improving psoriasis on patients with mild-to-moderate chronic plaque psoriasis. Scores for the psoriasis area-and severity index already started to decrease after one month of treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP05002383A 2004-12-09 2005-02-04 Composition contenant du TGF-beta et des protéines pour traiter le psoriasis Ceased EP1669086A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/007,912 US20060127493A1 (en) 2004-12-09 2004-12-09 Composition for treating psoriasis
CA002489851A CA2489851A1 (fr) 2004-12-09 2004-12-09 Composition pour traiter le psoriasis

Publications (1)

Publication Number Publication Date
EP1669086A1 true EP1669086A1 (fr) 2006-06-14

Family

ID=36013343

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05002383A Ceased EP1669086A1 (fr) 2004-12-09 2005-02-04 Composition contenant du TGF-beta et des protéines pour traiter le psoriasis

Country Status (1)

Country Link
EP (1) EP1669086A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006500A1 (fr) * 2001-07-13 2003-01-23 Pierre Jouan Biotechnologies S.A. Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques
JP2003089629A (ja) * 2001-09-18 2003-03-28 Kakunai Juyotai Kenkyusho:Kk 新規化粧品、新規外用剤及び新規浴剤の製造方法
DE10208034A1 (de) * 2002-02-26 2003-09-11 Helmut Otten Medikament sowie kosmetische und dermatologische Zubereitung enthaltend ein Büffelmilchprodukt
WO2003103705A1 (fr) * 2002-06-06 2003-12-18 Gropep Limited Inhibiteurs des metalloproteinases
WO2004004750A2 (fr) * 2002-07-05 2004-01-15 Institut Für Medizintechnologie Magdeburg Gmbh Imtm Utilisation d'inhibiteurs des alanyl-aminopeptidases et preparations pharmaceutiques contenant ces derniers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006500A1 (fr) * 2001-07-13 2003-01-23 Pierre Jouan Biotechnologies S.A. Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques
JP2003089629A (ja) * 2001-09-18 2003-03-28 Kakunai Juyotai Kenkyusho:Kk 新規化粧品、新規外用剤及び新規浴剤の製造方法
DE10208034A1 (de) * 2002-02-26 2003-09-11 Helmut Otten Medikament sowie kosmetische und dermatologische Zubereitung enthaltend ein Büffelmilchprodukt
WO2003103705A1 (fr) * 2002-06-06 2003-12-18 Gropep Limited Inhibiteurs des metalloproteinases
WO2004004750A2 (fr) * 2002-07-05 2004-01-15 Institut Für Medizintechnologie Magdeburg Gmbh Imtm Utilisation d'inhibiteurs des alanyl-aminopeptidases et preparations pharmaceutiques contenant ces derniers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 2003, Derwent World Patents Index; AN 2003-561912, XP002377085 *
DOI H. ET AL.: "Downregulation of TGF-beta isoforms and their receptors contribute to keratinocyte hyperproliferation in psoriasis vulgaris.", J. DERMATOL. SCI., vol. 33, no. 1, October 2003 (2003-10-01), pages 7 - 16, XP002376766 *

Similar Documents

Publication Publication Date Title
RU2445105C2 (ru) Дерматологическое применение молочных белков
Gorelick et al. Cerulein-induced pancreatitis
JP2021520373A (ja) Ｃｇｒｐを阻害する際に使用するための神経毒素
KR100996985B1 (ko) 글루카곤양 펩티드-１ 분비 촉진제, 글루카곤양 펩티드-１분비 촉진용 음식품, 식후 혈당값 상승 억제제 및 식후혈당값 상승 억제용 음식품
Targoni et al. Prevention of murine EAE by oral hydrolytic enzyme treatment
US9283269B2 (en) Method for reducing the allergenicity of animal dander
US7763257B2 (en) Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products
US10034911B2 (en) Chondrocyte proliferation promoting agent
JP4698935B2 (ja) 皮膚コラーゲン産生促進剤
US20100272708A1 (en) Method for the treatment of type and type iv hypersensitivity
US20060127493A1 (en) Composition for treating psoriasis
EP1669086A1 (fr) Composition contenant du TGF-beta et des protéines pour traiter le psoriasis
CA2489851A1 (fr) Composition pour traiter le psoriasis
CA2739715A1 (fr) Traitement ou prevention de la goutte
US10016481B2 (en) Sensation-improving agent
EP2144623B1 (fr) Procédé de fabrication d'une composition anti-inflammatoire à base de produit laitier
JP3108518B2 (ja) 胃潰瘍予防または治療のための医薬及び食品添加物
Olowookere The effect of total milk protein, casein and whey protein ingestion on blood glucose and insulin in rats
JP3007694B2 (ja) 胃潰瘍予防または治療のための医薬及び飲食品
JP2024539643A (ja) コラーゲン７タンパク質補充療法
WO1999049727A1 (fr) Composes de proteines antimicrobiens comme nouveaux agents hyperthermiques oraux de regulation du poids corporel et de l'hypertension

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17P Request for examination filed

Effective date: 20061213

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20070207

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20080727